Literature DB >> 17950884

The role of bisphosphonates in the management of patients that have cancer.

Timothy M Fan1.   

Abstract

Bisphosphonates are pharmacologic agents widely used in people for managing pathologic bone resorptive conditions. Based on their physicochemical properties, bisphosphonates concentrate within areas of active bone remodeling and induce osteoclast apoptosis. Appropriate use of bisphosphonates for treating companion animals requires a thorough understanding of how bisphosphonates exert their biologic effects. This review article highlights general properties of bisphosphonates, including their pharmacology, mechanisms of action, adverse side effects, anticancer mechanisms, surrogate markers for assessing response, and potential clinical utility for treating dogs and cats diagnosed with malignant skeletal tumors.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17950884     DOI: 10.1016/j.cvsm.2007.08.002

Source DB:  PubMed          Journal:  Vet Clin North Am Small Anim Pract        ISSN: 0195-5616            Impact factor:   2.093


  7 in total

1.  Models for anti-tumor activity of bisphosphonates using refined topochemical descriptors.

Authors:  Rakesh K Goyal; G Singh; A K Madan
Journal:  Naturwissenschaften       Date:  2011-09-04

2.  Zoledronic acid induces apoptosis via stimulating the expressions of ERN1, TLR2, and IRF5 genes in glioma cells.

Authors:  Cigir Biray Avci; Cansu Caliskan Kurt; Burcu Erbaykent Tepedelen; Ozgun Ozalp; Bakiye Goker; Zeynep Mutlu; Yavuz Dodurga; Levent Elmas; Cumhur Gunduz
Journal:  Tumour Biol       Date:  2015-12-08

3.  Treatment of ionized hypercalcemia in 12 cats (2006-2008) using PO-administered alendronate.

Authors:  B T Hardy; J F de Brito Galvao; T A Green; S R Braudaway; S P DiBartola; L Lord; D J Chew
Journal:  J Vet Intern Med       Date:  2015-01-12       Impact factor: 3.333

4.  Fracture rate and time to fracture in dogs with appendicular osteosarcoma receiving finely fractionated compared to coarsely fractionated radiation therapy: A single institution study.

Authors:  Carissa J Norquest; Charles A Maitz; Deborah A Keys; Melanie Moore; Jeffrey N Bryan; Tara J Ehling; Jimmy C Lattimer; Brian K Flesner
Journal:  Vet Med Sci       Date:  2022-03-08

5.  Retrospective Evaluation of Acute Kidney Injury After Zoledronic Acid Administration to Dogs With Malignant Osteolysis.

Authors:  Sarah A Vidal; Katherine A Skorupski; Jennifer L Willcox; Carrie A Palm; Jenna H Burton
Journal:  Front Vet Sci       Date:  2021-07-02

6.  Zoledronate-Associated Osteonecrosis of the Jaw in a Dog with Appendicular Osteosarcoma.

Authors:  A P Lundberg; P J Roady; A J Somrak; M E Howes; T M Fan
Journal:  J Vet Intern Med       Date:  2016-06-14       Impact factor: 3.333

7.  Medication-related osteonecrosis of the jaw after long-term bisphosphonate treatment in a cat.

Authors:  Melinda J Larson; Ashley B Oakes; Ember Epperson; Dennis J Chew
Journal:  J Vet Intern Med       Date:  2019-01-21       Impact factor: 3.333

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.